Epcoritamab Plus R<sup>2</sup> in Follicular Lymphoma: A Potential New Treatment Standard - Takeaways - MDSpire
Clinical Guidelines

Epcoritamab Plus R<sup>2</sup> in Follicular Lymphoma: A Potential New Treatment Standard

In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of di...

  • By

  • Caroline Helwick

  • April 22, 2026

  • 9 min

Share

  • 1

    Epcoritamab-R2 reduced disease progression risk by 80% compared to R2 alone.

  • 2

    The study involved 488 relapsed follicular lymphoma patients.

  • 3

    Epcoritamab enhances progression-free survival and overall response rates.

  • 4

    Outpatient treatment administration is possible, increasing patient access.

  • 5

    Safety profiles showed manageable side effects, mainly neutropenia.

  • 6

    Results suggest a shift in standard-of-care treatment for follicular lymphoma.

Original Source(s)

Epcoritamab Plus R<sup>2</sup> in Follicular Lymphoma: A Potential New Treatment Standard

  • by Caroline Helwick

  • April 22, 2026

Related Content

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies

  • May 12, 2026

  • 3 min
Complex Hematologic Malignancy Management in a TP53-Mutated Patient: Balancing Disease Control and Quality of Life

Cytogenetic and molecular testing revealed a complex karyotype and a TP53 mutation, placing her disease in an adverse-risk category.

  • by

  • April 27, 2026

  • 5 min
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs

Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published ...